Pro-Dex (PDEX) Projected to Post Earnings on Thursday

Key Points

• Pro-Dex is expected to report Q4 2026 earnings after the market closes Thursday, September 3, with analysts forecasting $0.67 in earnings per share and $19.20 million in revenue.
• Shares opened at $63.84 and are down 2.1%; the stock trades near its 52-week high, with a market capitalization of approximately $203.7 million.
• Analyst sentiment is mixed, with an overall “Hold” rating and a $70 consensus price target, while institutional investors own 15.28% of the company and several increased their positions.

Pro-Dex (NASDAQ:PDEX - Get Free Report) is expected to be issuing its Q4 2026 results after the market closes on Thursday, September 3rd. Analysts expect Pro-Dex to post earnings of $0.67 per share and revenue of $19.20 million for the quarter. Investors can find conference call details on the company's upcoming Q4 2026 earning report for the latest details on the call scheduled for Friday, September 4, 2026 at 4:00 PM ET.

Pro-Dex Stock Down 2.1%

PDEX opened at $63.84 on Thursday. Pro-Dex has a fifty-two week low of $23.47 and a fifty-two week high of $69.86. The firm has a market capitalization of $203.65 million, a P/E ratio of 17.64 and a beta of 0.02. The company's 50-day moving average is $61.99 and its 200 day moving average is $55.72. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.67 and a quick ratio of 2.14.

Wall Street Analyst Weigh In

Several research firms have commented on PDEX. Weiss Ratings lowered shares of Pro-Dex from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday. Zacks Research upgraded Pro-Dex to a "hold" rating in a research note on Tuesday, May 19th. Wall Street Zen raised Pro-Dex from a "hold" rating to a "buy" rating in a report on Saturday, June 13th. Finally, Ascendiant Capital Markets upped their target price on Pro-Dex from $56.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $70.00.

Institutional Trading of Pro-Dex

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Pro-Dex by 93.2% during the 2nd quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier's stock valued at $2,255,000 after buying an additional 24,927 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Pro-Dex by 67.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier's stock worth $1,566,000 after buying an additional 14,479 shares during the period. Punch & Associates Investment Management Inc. grew its stake in Pro-Dex by 42.1% in the 3rd quarter. Punch & Associates Investment Management Inc. now owns 48,608 shares of the medical instruments supplier's stock valued at $1,645,000 after buying an additional 14,408 shares in the last quarter. Jane Street Group LLC bought a new stake in Pro-Dex during the 1st quarter valued at $321,000. Finally, LPL Financial LLC bought a new stake in Pro-Dex during the 4th quarter valued at $228,000. 15.28% of the stock is currently owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source